8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

September 12, 2019

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware	001 - 27072	52-0845822
(state or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

2117 SW Highway 484, Ocala FL	34473
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AIM	NYSE American

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 12, 2019, the Board of Directors held a telephonic meeting to unanimously appoint Ellen Lintal as the Company’s new Chief Financial Officer, effective September 15, 2019. Ms. Lintal joined the Company in 2018 as Vice President of Finance & Control, before being promoted to Chief Accounting Officer earlier this year. Before joining AIM ImmunoTech, Ms. Lintal spent a decade at an international non-profit organization, serving as Chief Financial Officer and SVP of Finance & Control. Her more than 25-year career also includes public company accounting experience at Corning Inc., Carlisle Companies and AGY, where she participated in executing key priorities specializing in financial management, strategic planning and mergers and acquisitions.

There are no family relationships between Ms. Lintal and the Company’s directors, executive officers or persons nominated or charged by us to become directors or executive officers. There was no transaction during the last two years, or any proposed transactions, to which the Company was or is to be a party, in which Ms. Lintal had or is to have a direct or indirect material interest, other than Ms. Lintal serving as an employee of the Company.

On September 16, 2019, the Company issued a press release regarding Ms. Lintal’s appointment. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated September 16, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM ImmunoTech Inc.
September 16, 2019	By:	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

EX-99.1

Exhibit 99.1

AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

OCALA, Fla., September 16, 2019 — AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — today named Ellen Lintal as its new Chief Financial Officer.

The Board of Directors unanimously approved Lintal for the senior leadership position. She succeeds Adam Pascale, who stepped down after more than two decades with the company. Lintal joined the company — then named Hemispherx Biopharma Inc. — in 2018 as Vice President of Finance & Control, before being promoted to Chief Accounting Officer earlier this year.

“Ellen has proven herself to be an invaluable member of our Company and I’m grateful to have her join our senior leadership team,” said CEO Thomas K. Equels. “Her extensive experience in finance management and with public company accounting — especially in mergers and acquisitions — may be critical as we continue to move our drug Ampligen through multiple oncology clinical trials and, if those trials are successful, prepare for out-licensing or the acquisition of Ampligen in oncology.”

Before joining AIM ImmunoTech, Lintal spent a decade at an international non-profit organization, serving as Chief Financial Officer and SVP of Finance & Control. Her more than 25-year career also includes public company accounting experience at Corning Inc., Carlisle Companies and AGY, where she participated in executing key priorities specializing in financial management, strategic planning and mergers and acquisitions.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers. AIM’s flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen^® or Rintamod^®) and the FDA-approved drug Alferon N Injection^®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen^® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen^® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For example, no assurance can be given as to whether the current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data. Among other things, for forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contacts:

Crescendo Communications, LLC

Phone: 212-671-1021

Email: aim@crescendo-ir.com

Hayden IR

Phone: 646-755-7412

Email: James@HaydenIR.com

AIM ImmunoTech Inc.

Phone: 800-778-4042

Email: IR@aimimmuno.com